COGT Cogent Biosciences, Inc.

NASDAQ
$37.93

Cogent Biosciences, Inc. (COGT) is expected to report earnings on November 9, 2026, before the market open. The consensus earnings estimate is a loss of $0.57 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -6.2% since its last earnings release on August 10, 2026.

Cogent Biosciences Beat Consensus Estimates
Monday, August 10, 2026 · 8:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 9
Monday · 8:00 AM ET
Earnings Whisper
-
vs ($0.57)
Rev est $8.56M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $38.95

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Cogent Biosciences, Inc.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, CGT9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow